These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39054718)

  • 1. Genomic Alterations and Clinical Characterization in Chinese Patients with Metastatic Colorectal Cancer.
    Zhang XH; Zhou JQ; Wei Q; Li J; Xu T; Bai CM; Zhou JF; Wang XC
    Discov Med; 2024 Jul; 36(186):1477-1485. PubMed ID: 39054718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.
    Liu Y; Bischof E; Chen Z; Zhou J; Zhang B; Zhang D; Gao Y; Quan M
    Oncol Res; 2024; 32(9):1429-1438. PubMed ID: 39220126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Alterations of NTRK, POLE, ERBB2, and Microsatellite Instability Status in Chinese Patients with Colorectal Cancer.
    Guo Y; Guo XL; Wang S; Chen X; Shi J; Wang J; Wang K; Klempner SJ; Wang W; Xiao M
    Oncologist; 2020 Nov; 25(11):e1671-e1680. PubMed ID: 32627883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
    Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
    Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience.
    Gong J; Cho M; Sy M; Salgia R; Fakih M
    Oncotarget; 2017 Jun; 8(26):42198-42213. PubMed ID: 28178681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variation in KRAS/NRAS/BRAF-Mutation Status by Age, Sex, and Race/Ethnicity Among a Large Cohort of Patients with Metastatic Colorectal Cancer (mCRC).
    Booker BD; Markt SC; Schumacher FR; Rose J; Cooper G; Selfridge JE; Koroukian SM
    J Gastrointest Cancer; 2024 Mar; 55(1):237-246. PubMed ID: 37355486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER Project.
    Lee Y; Lee S; Sung JS; Chung HJ; Lim AR; Kim JW; Choi YJ; Park KH; Kim YH
    Cancer Res Treat; 2021 Jan; 53(1):123-130. PubMed ID: 32810930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer.
    Santos FA; Reis RM; Barroti LC; Pereira AAL; Matsushita MM; de Carvalho AC; Datorre JG; Berardinelli GN; Araujo RLC
    J Gastrointest Cancer; 2024 Mar; 55(1):344-354. PubMed ID: 37608030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of
    Bourhis A; De Luca C; Cariou M; Vigliar E; Barel F; Conticelli F; Marcorelles P; Nousbaum JB; Robaszkiewicz M; Samaison L; Badic B; Doucet L; Troncone G; Uguen A
    J Clin Pathol; 2020 Nov; 73(11):741-747. PubMed ID: 32273401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients.
    Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H
    Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis.
    Nunes L; Aasebø K; Mathot L; Ljungström V; Edqvist PH; Sundström M; Dragomir A; Pfeiffer P; Ameur A; Ponten F; Mezheyeuski A; Sorbye H; Sjöblom T; Glimelius B
    Acta Oncol; 2020 Apr; 59(4):417-426. PubMed ID: 31924107
    [No Abstract]   [Full Text] [Related]  

  • 15. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.
    Sorbye H; Dragomir A; Sundström M; Pfeiffer P; Thunberg U; Bergfors M; Aasebø K; Eide GE; Ponten F; Qvortrup C; Glimelius B
    PLoS One; 2015; 10(6):e0131046. PubMed ID: 26121270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions.
    Cocco E; Benhamida J; Middha S; Zehir A; Mullaney K; Shia J; Yaeger R; Zhang L; Wong D; Villafania L; Nafa K; Scaltriti M; Drilon A; Saltz L; Schram AM; Stadler ZK; Hyman DM; Benayed R; Ladanyi M; Hechtman JF
    Cancer Res; 2019 Mar; 79(6):1047-1053. PubMed ID: 30643016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.
    Lee SM; Oh H
    Sci Rep; 2024 May; 14(1):11432. PubMed ID: 38763942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.